Since there have been no other findings to show that crovalimab, a novel subcutaneous C5 inhibitor, improves platelet counts, a registry study of crovalimab-treated PNH patients with bone marrow failure is warranted. The gene discussed is C5; the disease is Bone marrow hypocellularity.